|
Market Closed -
Other stock markets
|
Pre-market 09:05:35 am | |||
| 174.37 USD | -0.74% |
|
174.48 | +0.06% |
| 03:01pm | Vraylar sales growth seen slowing in 2025, says Richter CEO | RE |
| Dec. 11 | AbbVie Closes Aliada Therapeutics Acquisition | MT |
| Capitalization | 308B 294B 272B 242B 436B 26,126B 484B 3,385B 1,253B 10,743B 1,158B 1,132B 46,986B | P/E ratio 2024 * |
36.5x | P/E ratio 2025 * | 23.7x |
|---|---|---|---|---|---|
| Enterprise value | 366B 349B 324B 287B 517B 31,029B 575B 4,020B 1,489B 12,760B 1,375B 1,344B 55,803B | EV / Sales 2024 * |
6.53x | EV / Sales 2025 * | 6.03x |
| Free-Float |
96.39% | Yield 2024 * |
3.57% | Yield 2025 * | 3.74% |
More valuation ratios
* Estimated data
More news
Last Transcript: AbbVie Inc.
More recommendations
More press releases
More news
| 1 day | +1.54% | ||
| 1 week | -1.18% | ||
| Current month | -4.68% | ||
| 1 month | -0.03% | ||
| 3 months | -10.39% | ||
| 6 months | +3.98% | ||
| Current year | +12.52% |
1 week
173.83
178.13
1 month
163.81184.24
Current year
153.58207.32
1 year
151.29207.32
3 years
125.20207.32
5 years
62.55207.32
10 years
45.45207.32
| Director | Title | Age | Since |
|---|---|---|---|
Robert Michael
CEO | Chief Executive Officer | 53 | 2024-06-30 |
Scott Reents
DFI | Director of Finance/CFO | 57 | 2022-06-22 |
Roopal Thakkar
CTO | Chief Tech/Sci/R&D Officer | - | 2002-12-31 |
| Manager | Title | Age | Since |
|---|---|---|---|
Richard Gonzalez
CHM | Chairman | 70 | 2012-12-31 |
Roxanne Austin
BRD | Director/Board Member | 63 | 2012-12-31 |
William Burnside
BRD | Director/Board Member | 72 | 2012-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.12% | 7 M€ | +17.91% | - | |
| 6.85% | 20 M€ | +16.68% | - | |
| 6.26% | 13 M€ | -.--% |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -0.74% | -1.18% | +15.29% | +38.97% | 308B | ||
| -0.44% | -4.07% | +36.30% | +226.05% | 717B | ||
| -0.35% | +1.89% | +18.85% | +106.17% | 492B | ||
| -1.74% | -2.55% | -5.43% | -11.39% | 353B | ||
| -1.24% | -1.60% | -4.43% | +37.36% | 252B | ||
| -0.51% | -0.90% | +0.12% | -32.32% | 232B | ||
| -0.41% | -1.17% | +3.17% | +27.23% | 208B | ||
| +0.20% | -2.60% | +2.44% | +18.10% | 199B | ||
| -0.85% | -1.74% | +0.47% | +29.65% | 147B | ||
| -1.33% | 0.00% | -11.91% | -52.20% | 143B | ||
| Average | -0.15% | -1.00% | +5.49% | +38.76% | 305.16B | |
| Weighted average by Cap. | -0.14% | -1.39% | +11.96% | +75.47% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 56.04B 53.45B 49.56B 43.96B 79.25B 4,752B 88.03B 616B 228B 1,954B 211B 206B 8,546B | 59.2B 56.46B 52.35B 46.44B 83.71B 5,019B 92.99B 650B 241B 2,064B 222B 217B 9,027B |
| Net income | 8.1B 7.72B 7.16B 6.35B 11.45B 687B 12.72B 88.98B 32.95B 282B 30.43B 29.75B 1,235B | 12.07B 11.51B 10.68B 9.47B 17.07B 1,024B 18.96B 133B 49.11B 421B 45.35B 44.35B 1,841B |
| Net Debt | 57.82B 55.15B 51.13B 45.36B 81.76B 4,903B 90.82B 635B 235B 2,016B 217B 212B 8,817B | 48.92B 46.66B 43.26B 38.38B 69.18B 4,148B 76.85B 537B 199B 1,706B 184B 180B 7,460B |
More financial data
* Estimated data
Employees
50,000
Sector
Pharmaceuticals
Calendar
2025-01-14
- Détachement de
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-12-11 | 174.37 $ | -0.74% | 9,492,204 |
| 24-12-10 | 175.67 $ | -0.51% | 4,089,569 |
| 24-12-09 | 176.57 $ | +0.22% | 4,394,811 |
| 24-12-06 | 176.19 $ | +0.01% | 4,839,640 |
| 24-12-05 | 176.17 $ | -0.16% | 5,444,240 |
Delayed Quote Nyse, December 11, 2024 at 04:01 pm EST
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
174.37USD
Average target price
202.26USD
Spread / Average Target
+15.99%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ABBV Stock